These nanoparticles are capable of selectively delivering conjugated drugs or cytotoxic protein domains to cancer cells that overexpress the CXCR4 receptor (CXCR4+) in cancer tissues, avoiding their delivery in healthy organs because of the low or negligible CXCR4 expression level in normal cells [12,13]. This evidence concerns the gene CXCR4 and cancer.